Key Points
- COO Elizabeth Bhatt sold 4,000 Septerna shares on April 15 at an average price of $24.34 for $97,360, leaving her with 174,209 shares (a 2.24% reduction); she also sold 4,000 shares on Feb. 18 at $28.97.
- Company outlook is mixed: Septerna (market cap $1.17B) reported a Q1 miss (EPS -$0.24 vs. -$0.23 estimate) and large negative margins and ROE, yet analysts collectively rate the stock a "Moderate Buy" with an average target of $43.14 and several firms issuing buy/overweight ratings and high targets up to $60.
Septerna, Inc. (NASDAQ:SEPN - Get Free Report) COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $24.34, for a total value of $97,360.00. Following the completion of the transaction, the chief operating officer directly owned 174,209 shares in the company, valued at $4,240,247.06. The trade was a 2.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Elizabeth Bhatt also recently made the following trade(s):
- On Wednesday, February 18th, Elizabeth Bhatt sold 4,000 shares of Septerna stock. The shares were sold at an average price of $28.97, for a total value of $115,880.00.
Septerna Price Performance
Septerna stock opened at $26.13 on Friday. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -23.54 and a beta of 3.50. The company's 50 day simple moving average is $26.20 and its 200 day simple moving average is $25.09. Septerna, Inc. has a fifty-two week low of $5.73 and a fifty-two week high of $32.63.
Septerna (NASDAQ:SEPN - Get Free Report) last posted its earnings results on Monday, March 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.01). Septerna had a negative return on equity of 15.85% and a negative net margin of 106.37%. As a group, analysts predict that Septerna, Inc. will post -7.11 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently commented on the company. JonesTrading started coverage on Septerna in a research report on Tuesday, December 23rd. They set a "buy" rating and a $43.00 price target on the stock. Raymond James Financial assumed coverage on Septerna in a research note on Friday, December 19th. They set a "strong-buy" rating and a $38.00 target price for the company. Wells Fargo & Company raised their target price on shares of Septerna from $28.00 to $48.00 and gave the stock an "overweight" rating in a report on Tuesday, March 3rd. Weiss Ratings restated a "sell (d-)" rating on shares of Septerna in a report on Thursday, January 22nd. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $60.00 price target on shares of Septerna in a research note on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $43.14.
Read Our Latest Research Report on SEPN
Institutional Trading of Septerna
A number of institutional investors have recently modified their holdings of SEPN. Goldman Sachs Group Inc. boosted its position in shares of Septerna by 86.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company's stock worth $75,698,000 after buying an additional 1,260,409 shares during the period. Vanguard Group Inc. lifted its stake in Septerna by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company's stock valued at $28,568,000 after acquiring an additional 104,394 shares in the last quarter. Avoro Capital Advisors LLC boosted its position in Septerna by 8.1% during the 3rd quarter. Avoro Capital Advisors LLC now owns 1,337,500 shares of the company's stock worth $25,158,000 after acquiring an additional 100,000 shares during the last quarter. ADAR1 Capital Management LLC grew its stake in shares of Septerna by 38.9% during the 3rd quarter. ADAR1 Capital Management LLC now owns 1,176,491 shares of the company's stock worth $22,130,000 after acquiring an additional 329,264 shares in the last quarter. Finally, First Light Asset Management LLC acquired a new stake in shares of Septerna in the fourth quarter valued at approximately $17,308,000.
Septerna Company Profile
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
